Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy

Antiviral Therapy

Volumn 22, Issue 1, 2017, Pages 61-70

  Ogawa, Eiichi ^a   Furusyo, Norihiro ^a   Murata, Masayuki ^a   Shimizu, Motohiro ^a   Toyoda, Kazuhiro ^a   Hotta, Taeko ^a   Uchiumi, Takeshi ^a   Hayashi, Jun ^b  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b Haradoi Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; DACLATASVIR; LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ADULT; AGED; ANTIRETROVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG MONITORING; DRUG RESPONSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION SYSTEM; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC HEPATITIS C; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; ISOLATION AND PURIFICATION; KINETICS; MIDDLE AGED; PROCEDURES; VIROLOGY; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; FEMALE; FLUORENES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KINETICS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; SOFOSBUVIR; URIDINE MONOPHOSPHATE; VIRAL LOAD;

EID: 85015967342     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3085     Document Type: Article

References (23)

1. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538.
2. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20:17-35.
3. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62:932-954.
4. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60:392-420.
5. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-1342.
6. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008; 49:634-651.
7. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferonalpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47:1260-1269.
8. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135:451-458.
9. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47:43-50.
10. Ogawa E, Furusyo N, Murata M, et al. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevirbased triple therapy: a comparison of two real-time PCR assays. Antiviral Res 2013; 99:119-124.
11. Maasoumy B, Hunyady B, Calvaruso V, et al. Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. PLoS One 2014; 9:e110857.
12. Fevery B, Susser S, Lenz O, et al. Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir. J Clin Virol 2015; 72:133-140.
13. Ogawa E, Furusyo N, Murata M, et al. Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy. Antiviral Res 2016; 126:35-42.
14. Backus LI, Belperio PS, Shahoumian TA, et al. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis C infected patients. Hepatology 2016; 64:405-414.
15. Ioannou GN, Beste LA, Chang MF, et al. Effectiveness of sofosbuvir, ledipasvir/sofosbuvir, or paritaprevir/ritonavir/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Healthcare System. Gastroenterology 2016; 151:457-471.
16. Sidharthan S, Kohli A, Sims Z, et al. Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clin Infect Dis 2015; 60:1743-1751.
17. Maasoumy B, Vermehren J, Welker MW, et al. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. J Hepatol 2016; 65:473-482.
18. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20:15-20.
19. Ogawa E, Furusyo N, Toyoda K, et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83:127-134.
20. Furusyo N, Ogawa E, Murata M, et al. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. J Antimicrob Chemother 2014; 69:483-490.
21. Ogawa E, Furusyo N, Kajiwara E, et al. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. J Gastroenterol Hepatol 2015; 30:1759-1767.
22. Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014; 124:3352-3363.
23. + T cell function by interferon-free therapy. J Hepatol 2014; 61:538-543.